All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99


Relative Articles


A Novel LNP-Based Chlamydia Subunit Vaccine Formulation That Induces Th1 Responses without Upregulating IL-17 Provides Equivalent Protection in Mice as Formulations That Induced IL-17 and Th1 Cytokines

DOI: 10.4236/wjv.2020.104005, PP. 55-75

Keywords: LNP, Chlamydia, IL-17, Mouse Model, Th1 Cytokines

Full-Text   Cite this paper   Add to My Lib


We evaluated novel Chlamydial vaccines, consisting of major outer membrane protein (MOMP) alone or in combination with polymorphic membrane proteins D (PmpD) and G (PmpG) using a C57BL/6 mouse model. Native MOMP (nMOMP) isolated from C. muridarum elementary bodies (EBs) and recombinant PmpD and PmpG proteins were adjuvanted with Monophosphoryl lipid A (MPLA), with either lipid nanoparticles (LNPs) or the cationic lipid dimethyldioctadecylammonium bromide (DDA). Antibody titers to C. muridarum nMOMP, and EBs were evaluated by ELISA, and T-cell responses were analyzed by intracellular cytokine staining (ICS). Protection from challenge was determined by qPCR. Vaccine immunized mice showed significantly higher antibody titers to nMOMP (P < 0.001) and C. muridarum EBs (P < 0.001), when compared to the adjuvant alone group. Antibody titers in vaccine groups with Monophosphoryl lipid A (MPLA) + LNP were higher as compared to the MPLA + DDA group (P < 0.001) except for (Cm nMOMP + PmpG + PmpD p73 + PmpD p82 + MPLA + DDA) vs (Cm nMOMP + PmpG + PmpD p73 + PmpD p82 + MPLA + LNP) for both C. muridarum EBs and PmpG. ICS analysis showed more robust CD4 + T-cell responses (IFN-γ/IL-2/TNF-a) in the DDA and LNP groups compared to the adjuvant alone group. The DDA + MPLA gave robust Th17 responses in comparison to MPLA and LNP group. Mice immunized with Chlamydia antigens also showed protection from C. muridarum challenge, by reduction in bacterial shedding for all groups (P < 0.003) compared to shedding from the adjuvant control. Both vaccine formulations generated robust immunological responses, and both were protective by reducing bacterial shedding after challenge. This data indicates equal protection can be achieved without the induction of Th17 responses.


[1]  Beagley, K.W. and Timms, P. (2000) Chlamydia trachomatis Infection: Incidence, Health Costs and Prospects for Vaccine Development. Journal of Reproductive Immunology, 48, 47-68.
[2]  Brunham, R.C. and Rey-Ladino, J. (2005) Immunology of Chlamydia Infection: Implications for a Chlamydia trachomatis Vaccine. Nature Reviews Immunology, 5, 149-161.
[3]  Morrison, R.P. and Caldwell, H.D. (2002) Immunity to Murine Chlamydial Genital Infection. Infection and Immunity, 70, 2741-2751.
[4]  Gerbase, A.C., Rowley, J.T., Heymann, D.H.L., Berkley, S.F.B. and Piot, P. (1998) Global Prevalence and Incidence Estimates of Selected Curable STDs. Sexually Transmitted Infections, 74, S12-S16.
[5]  CDC (2004) Chlamydia Screening among Sexually Active Young Female Enrollees of Health Plans—United States, 1999-2001. Morbidity and Mortality Weekly Report, 53, 983-985.
[6]  Pal, S., Tatarenkova, O.V. and de la Maza, L.M. (2015) A Vaccine Formulated with the Major Outer Membrane Protein Can Protect C3H/HeN, a Highly Susceptible Strain of Mice, from a Chlamydia muridarum Genital Challenge. Immunology, 146, 432-443.
[7]  Pal, S., Peterson, E.M., Rappuoli, R., Ratti, G. and de la Maza, L.M. (2006) Immunization with the Chlamydia trachomatis Major Outer Membrane Protein, Using Adjuvants Developed for Human Vaccines, Can Induce Partial Protection in a Mouse Model against a Genital Challenge. Vaccine, 24, 766-775.
[8]  Pal, S., Theodor, I., Peterson, E.M. and de la Maza, L.M. (1997) Immunization with an Acellular Vaccine Consisting of the Outer Membrane Complex of Chlamydia trachomatis Induces Protection against a Genital Challenge. Infection and Immunity, 65, 3361-3369.
[9]  Yu, H., Jiang, X., Shen, C., Karunakaran, K.P., Jiang, J., Rosin, N.L., et al. (2010) Chlamydia muridarum T-Cell Antigens Formulated with the Adjuvant DDA/TDB Induce Immunity against Infection That Correlates with a High Frequency of Gamma Interferon (IFN-Gamma)/Tumor Necrosis Factor Alpha and IFN-Gamma/Interleukin-17 Double-Positive CD4+ T Cells. Infection and Immunity, 78, 2272-2282.
[10]  Yu, H., Karunakaran, K.P., Jiang, X. and Brunham, R.C. (2014) Evaluation of a Multisubunit Recombinant Polymorphic Membrane Protein and Major Outer Membrane Protein T Cell Vaccine against Chlamydia muridarum Genital Infection in Three Strains of Mice. Vaccine, 32, 4672-4680.
[11]  Yu, H., Karunakaran, K.P., Jiang, X. and Brunham, R.C. (2016) Subunit Vaccines for the Prevention of Mucosal Infection with Chlamydia trachomatis. Expert Review of Vaccines, 15, 977-988.
[12]  Karunakaran, K.P., Yu, H., Jiang, X., Chan, Q., Moon, K.M., Foster, L.J., et al. (2015) Outer Membrane Proteins Preferentially Load MHC Class II Peptides: Implications for a Chlamydia trachomatis T Cell Vaccine. Vaccine, 33, 2159-2166.
[13]  Yu, H., Jiang, X., Shen, C., Karunakaran, K.P. and Brunham, R.C. (2009) Novel Chlamydia muridarum T Cell Antigens Induce Protective Immunity against Lung and Genital Tract Infection in Murine Models. The Journal of Immunology, 182, 1602-1608.
[14]  Ralli-Jain, P., Tifrea, D., Cheng, C., Pal, S. and de la Maza, L.M. (2010) Enhancement of the Protective Efficacy of a Chlamydia trachomatis Recombinant Vaccine by Combining Systemic and Mucosal Routes for Immunization. Vaccine, 28, 7659-7666.
[15]  Vicetti Miguel, R.D., Quispe Calla, N.E., Pavelko, S.D. and Cherpes, T.L. (2016) Intravaginal Chlamydia trachomatis Challenge Infection Elicits TH1 and TH17 Immune Responses in Mice That Promote Pathogen Clearance and Genital Tract Damage. PLoS ONE, 11, e0162445.
[16]  Scurlock, A.M., Frazer, L.C., Andrews, C.W., O’Connell, C.M., Foote, I.P., Bailey, S.L., et al. (2011) Interleukin-17 Contributes to Generation of Th1 Immunity and Neutrophil Recruitment during Chlamydia muridarum Genital Tract Infection But Is Not Required for Macrophage Influx or Normal Resolution of Infection. Infection and Immunity, 79, 1349-1362.
[17]  O’Meara, C.P., Harvie, M.C., Andrew, D.W., Timms, P., Lycke, N.Y. and Beagley, K.W. (2014) Immunity against a Chlamydia Infection and Disease May Be Determined by a Balance of IL-17 Signaling. Immunology and Cell Biology, 92, 287-297.
[18]  Lindenstrom, T., Woodworth, J., Dietrich, J., Aagaard, C., Andersen, P. and Agger, E.M. (2012) Vaccine-Induced th17 Cells Are Maintained Long-Term Post-Vaccination as a Distinct and Phenotypically Stable Memory Subset. Infection and Immunity, 80, 3533-3544.
[19]  Swanson, K.A., Taylor, L.D., Frank, S.D., Sturdevant, G.L., Fischer, E.R., Carlson, J.H., et al. (2009) Chlamydia trachomatis Polymorphic Membrane Protein D Is an Oligomeric Autotransporter with a Higher-Order Structure. Infection and Immunity, 77, 508-516.
[20]  Wooters, M.A., Kaufhold, R.M., Field, J.A., Indrawati, L., Heinrichs, J.H. and Smith, J.G. (2009) A Real-Time Quantitative Polymerase Chain Reaction Assay for the Detection of Chlamydia in the Mouse Genital Tract Model. Diagnostic Microbiology and Infectious Disease, 63, 140-147.
[21]  Hepler, R.W., Nahas, D.D., Lucas, B., Kaufhold, R., Flynn, J.A., Galli, J.D., Swoyer, R., Wagner, J.M., Espeseth, A.S., Joyce, J.G., Cook, J.C. and Durr, E. (2018) Spectroscopic Analysis of Chlamydial Major Outer Membrane Protein in Support of Structure Elucidation. Protein Science: A Publication of the Protein Society, 27, 1923-1941.
[22]  Morrison, R., Feilzer, K. and Tumas, D.B. (1995) Gene Knockout Mice Establish a Primary Protective Role for Major Histocompatibility Complex Class II-Restricted Responses in Chlamydia trachomatis Genital Tract Infection. Infection and Immunity, 63, 4661-4668.
[23]  Morrison, S.G. and Morrison, R.P. (2001) Resolution of Secondary Chlamydia trachomatis Genital Tract Infection in Immune Mice with Depletion of Both CD4+ and CD8+ T Cells. Infection and Immunity, 69, 2643-2649.
[24]  Morrison, S.G., Su, H., Caldwell, H.D. and Morrison, R.P. (2000) Immunity to Murine Chlamydia trachomatis Genital Tract Reinfection Involves B Cells and CD4(+) T Cells But Not CD8(+) T Cells. Infection and Immunity, 68, 6979-6987.
[25]  Rank, R.G., Soderberg, L.S. and Barron, A.L. (1985) Chronic Chlamydial Genital Infection in Congenitally Athymic Nude Mice. Infection and Immunity, 48, 847-849.
[26]  Lu, C., Zeng, H., Li, Z., Lei, L., Yeh, I.T., Wu, Y., et al. (2012) Protective Immunity against Mouse Upper Genital Tract Pathology Correlates with High IFNgamma But Low IL-17 T Cell and Anti-Secretion Protein Antibody Responses Induced by Replicating Chlamydial Organisms in the Airway. Vaccine, 30, 475-485.
[27]  Yu, H., Karunakaran, K.P., Kelly, I., Shen, C., Jiang, X., Foster, L.J., et al. (2011) Immunization with Live and Dead Chlamydia muridarum Induces Different Levels of Protective Immunity in a Murine Genital Tract Model: Correlation with MHC Class II Peptide Presentation and Multifunctional Th1 Cells. The Journal of Immunology, 186, 3615-3621.
[28]  Farris, C.M., Morrison, S.G. and Morrison, R.P. (2010) CD4+ T Cells and Antibody Are Required for Optimal Major Outer Membrane Protein Vaccine-Induced Immunity to Chlamydia muridarum Genital Infection. Infection and Immunity, 78, 4374-4383.
[29]  Igietseme, J.U. and Rank, R.G. (1991) Susceptibility to Reinfection after a Primary Chlamydial Genital Infection Is Associated with a Decrease of Antigen-Specific T Cells in the Genital Tract. Infection and Immunity, 59, 1346-1351.
[30]  Morrison, S.G. and Morrison, R.P. (2005) A Predominant Role for Antibody in Acquired Immunity to Chlamydial Genital Tract Reinfection. The Journal of Immunology, 175, 7536-7542.
[31]  Perry, L.L., Feilzer, K. and Caldwell, H.D. (1997) Immunity to Chlamydia trachomatis Is Mediated by T Helper 1 Cells through IFN-Gamma-Dependent and -Independent Pathways. The Journal of Immunology, 158, 3344-3352.
[32]  Roshick, C., Wood, H., Caldwell, H.D. and McClarty, G. (2006) Comparison of Gamma Interferon-Mediated Antichlamydial Defense Mechanisms in Human and Mouse Cells. Infection and Immunity, 74, 225-238.
[33]  Swaminathan, G., Thoryk, E.A., Cox, K.S., Meschino, S., Dubey, S.A., Vora, K.A., et al. (2016) A Novel Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Sub-Unit Vaccine Antigens. Vaccine, 34, 110-119.
[34]  Klinguer-Hamour, C., Libon, C., Plotnicky-Gilquin, H., Bussat, M.C., Revy, L., Nguyen, T., et al. (2002) DDA Adjuvant Induces a Mixed Th1/Th2 Immune Response When Associated with BBG2Na, a Respiratory Syncytial Virus Potential Vaccine. Vaccine, 20, 2743-2751.
[35]  Byrne RSS, G.I., Ada, G., Caldwell, H.D., Su, H., Morrison, R.P., Van Der Pol, B., Bavoil, P., Bobo, L., Everson, S., Ho, Y., Hsia, R.C., Kennedy, K., Kuo, C.-C., Montgomery, P.C., Peterson, E., Swanson, A., Whitaker, C., Whittum Hudson, J., Yang, C.L., Zhang, Y.-X. and Zhong, G.M. (1993) Workshop on In Vitro Neutralization of Chlamydia trachomatis: Summary of Proceedings. The Journal of Infectious Diseases, 168, 415-420.


comments powered by Disqus

Contact Us


WhatsApp +8615387084133

WeChat 1538708413